Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
AIDS
; 37(6): 941-946, 2023 05 01.
Article
in English
| MEDLINE | ID: covidwho-2222943
ABSTRACT
OBJECTIVE:
This study describes adverse events following immunization (AEFIs) and the development of SARS-COV-2 antibodies after Sputnik V, AstraZeneca, and Sinopharm COVID-19 vaccination in people with HIV (PWH).METHODS:
In total, 595 adult PWH at an HIV center in Argentina from March to December 2021 were enrolled. Analysis included participants who received COVID-19 vaccination with Sputnik V, AstraZeneca, and Sinopharm, and did not receive mRNA COVID-19 vaccines. Clinical data, and local or systemic AEFI variables were collected using an online questionnaire after the first dose. Detection of S1-RBD IgG antibodies was performed between days 28 and 60 after the second dose in a subsample (SARS-CoV-2 IgG chemiluminescent immunoassay; Siemens). A multivariable logistic regression and spearman test were used for analyses.RESULTS:
Mean age was 46.1âyears (SDâ=â11.8); 70.4% were men; and median CD4 + T cells count was 659 (500-852) cells/µl. AEFIs were reported in 214 (36.0%) participants. More participants reported AEFIs after Sputnik V (29.4%) and AstraZeneca (47.5%) than Sinopharm (13.9%) (χ 2 â=â35.85, P â<â0.001). Higher odds of reporting an AEFIs were associated with receiving Sputnik V [aORâ=â2.90; 95% confidence interval (95% CI) = 1.40-6.04; P â=â0.004] and AstraZeneca (aORâ=â5.38; 95% CI = 2.63-11.01; P â<â0.001) compared with Sinopharm. Lower odds were associated with age (aORâ=â0.97; 95% CI = 0.95-0.99; P â<â0.001). Overall, 76 (95.0%) individuals assessed for the presence of SARS-CoV-2 antibody reached S1-RBD IgG antibody titers at least 1âU/ml; mean titer was 51.3 (SDâ=â51.07) U/ml. Higher antibody titers correlated with higher CD4 + T cells count (Rhoâ=â0.280; P â=â0.012).CONCLUSION:
NonmRNA vaccines showed a good safety profile and adequate SARS-CoV-2 antibody responses among PWH suggesting adequate protection to SARS-CoV-2.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines
/
HIV Infections
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
AIDS
Journal subject:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS